Ocuphire Pharma (Ocuphire Pharma) Total Payout Ratio : 0.22 (As of May. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocuphire Pharma Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Ocuphire Pharma's current Total Payout Ratio is 0.22.

Ocuphire Pharma Total Payout Ratio Historical Data

The historical data trend for Ocuphire Pharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocuphire Pharma Total Payout Ratio Chart

Ocuphire Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

0.86

0.50

-0.25

0.92

Ocuphire Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial													-	-	-	-	0.34

Competitive Comparison of Ocuphire Pharma's Total Payout Ratio

For the Biotechnology subindustry, Ocuphire Pharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocuphire Pharma's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Ocuphire Pharma's Total Payout Ratio falls into.

Ocuphire Pharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Ocuphire Pharma's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	9.227	+	0)	/	-9.986
	=	0.92

Ocuphire Pharma's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-0.042	+	2.479	+	0)	/	-7.106
	=	0.34

Ocuphire Pharma Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Ocuphire Pharma's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocuphire Pharma (Ocuphire Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocuphire Pharma Inc (NAS:OCUP) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

R3X1:Germany

Address

37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335

Website

https://www.ocuphire.com

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Executives

George Magrath	officer: Chief Executive Officer	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel	officer: SVP, Operations & Bus. Dev.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch	director, officer: President and CEO	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J	director	5130 ROUTE 212, WILLOW NY 12495
Jay Pepose	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton	director	3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba	officer: VP of Finance	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer	director
Sean Ainsworth	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann	officer: VP of Corp. Dev. & Ops & Sec.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price	director	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky	officer: President and CFO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732